AGER/RAGE Antibody - #AF5309

(6)   (8)  
Product: AGER/RAGE Antibody
Catalog: AF5309
Description: Rabbit polyclonal antibody to AGER/RAGE
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 43~60kDa; 43kD(Calculated).
Uniprot: Q15109
RRID: AB_2837794

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(92%), Bovine(83%), Horse(83%), Sheep(83%), Rabbit(100%), Dog(83%)
Clonality:
Polyclonal
Specificity:
AGER/RAGE Antibody detects endogenous levels of total AGER/RAGE.
RRID:
AB_2837794
Cite Format: Affinity Biosciences Cat# AF5309, RRID:AB_2837794.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Advanced glycosylation end product-specific receptor; Ager; MGC2235; RAGE_HUMAN; Receptor for advanced glycosylation end products;

Immunogens

Immunogen:
Uniprot:

Q15109(RAGE_HUMAN) >>Visit HPA database.

Gene(ID):
AGER(177)
Expression:
Q15109 RAGE_HUMAN:

Endothelial cells.

Description:
Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes.
Sequence:
MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGVILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Rabbit
100
Pig
92
Horse
83
Bovine
83
Sheep
83
Dog
83
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q15109 As Substrate

Site PTM Type Enzyme
S391 Phosphorylation
S399 Phosphorylation
S400 Phosphorylation

Research Backgrounds

Function:

Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein.

Secreted.

Cell membrane>Single-pass type I membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Endothelial cells.

Subunit Structure:

Interacts with S100A1 and APP (By similarity). Interacts with S100B, S100A12 and S100A14. Constitutive homodimer; disulfide-linked.

References

1). Characterizing cellular heterogeneity in fibrotic hypersensitivity pneumonitis by single-cell transcriptional analysis. Cell Death Discovery, 2022 (PubMed: 35091537) [IF=7.0]

Application: IF/ICC    Species: Human    Sample: lung tissues

Fig. 4: Single-Cell transcriptional analysis unravels heterogeneity of fibroblasts during FHP.A t-SNE visualization of PLA2G2Ahigh fibroblasts, COL1A1high fibroblasts, TCF21high fibroblasts, and ACTA2high fibroblasts. B The heatmap showing the expression levels of top five marker genes in fibroblast subpopulations. C Relative percentage of fibroblast subpopulations in lung from the patient with FHP. D Violin plots displaying the expression levels of the representative genes in each fibroblast subpopulation. E Relative gene set enrichment scores of subpopulations calculated by AUCell analysis. F Multiplex immunofluorescence images of TCF21, ACTA2, and COL1A1 in lung tissues from FHP. Scale bar = 10 μm. G Trajectory analysis of PLA2G2Ahigh fibroblasts, COL1A1high fibroblasts, TCF21high fibroblasts, and ACTA2high fibroblasts using Monocle 2 (upper) and Velocyto R package (lower). H CEBPD_extended motif showed greater enrichment of regulon activity for PLA2G2Ahigh fibroblasts using SCENIC analysis (left panel). MEF2C_extended motif showed greater enrichment of regulon activity for ACTA2high fibroblasts (left panel). t-SNE visualization of AUC values of CEBPD_extended and MEF2C_extended motifs in fibroblasts (right panel). I Schematic developmental trajectories of fibroblast subpopulations in FHP lungs. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
2). Naringin ameliorates type 2 diabetes mellitus-induced steatohepatitis by inhibiting RAGE/NF-κB mediated mitochondrial apoptosis. LIFE SCIENCES, 2020 (PubMed: 32702445) [IF=6.1]

Application: IF/ICC    Species: rat    Sample: HepG2 cells

Fig. 4. |Naringin ameliorates NASH through modulation of the AGE/RAGE mechanism. The level of AGE was determined in HepG2 cells and plasma by (A) ELISA and(B) fluorimetry. Receptor for AGE (RAGE) was analyzed in HepG2 cells and liver tissue by (C) qPCR (n = 6) and (D and E) immunoblotting (n = 3). Expressions were normalized by GAPDH. RAGE expression was further validated by immunofluorescence in (F) cells, (G) its quantification (n = 5), and (H) tissue and (I) its quantification (n = 5) by using Alexa Fluor 594 (red), DAPI (blue). Magnification 40×. Data are shown as Mean ± S.E.M (n = 8), *Control vs NASH; #NASH vs NAR. **P < 0.01, ***P < 0.001; #P < 0.05, ##P < 0.01, ###P < 0.001.

Application: WB    Species: rat    Sample: HepG2 cells and liver tissue

Fig. 4. |Naringin ameliorates NASH through modulation of the AGE/RAGE mechanism. The level of AGE was determined in HepG2 cells and plasma by (A) ELISA and(B) fluorimetry. Receptor for AGE (RAGE) was analyzed in HepG2 cells and liver tissue by (C) qPCR (n = 6) and (D and E) immunoblotting (n = 3). Expressions were normalized by GAPDH. RAGE expression was further validated by immunofluorescence in (F) cells, (G) its quantification (n = 5), and (H) tissue and (I) its quantification (n = 5) by using Alexa Fluor 594 (red), DAPI (blue). Magnification 40×. Data are shown as Mean ± S.E.M (n = 8), *Control vs NASH; #NASH vs NAR. **P < 0.01, ***P < 0.001; #P < 0.05, ##P < 0.01, ###P < 0.001.
3). Identification of S100A8/A9 involved in thromboangiitis obliterans development using tandem mass tags-labeled quantitative proteomics analysis. Cellular signalling, 2024 (PubMed: 38697446) [IF=4.3]
4). Network-pharmacology-based research on protective effects and underlying mechanism of Shuxin decoction against myocardial ischemia/reperfusion injury with diabetes. World journal of diabetes, 2023 (PubMed: 37547579) [IF=4.2]
5). HMGB1/RAGE axis mediates the apoptosis, invasion, autophagy, and angiogenesis of the renal cell carcinoma. OncoTargets and Therapy, 2018 (PubMed: 30122942) [IF=4.0]

Application: WB    Species: human    Sample: RCC cell

Figure 1 |HMGB1 knockdown decreased the viability of A498 and ACHN cells.Notes: (A) The RAGE and HMGB1 proteins in RCC cell lines were detected by Western blot.
6). Anti-high-mobility group box-1 (HMGB1) mediates the apoptosis of alveolar epithelial cells (AEC) by receptor of advanced glycation end-products (RAGE)/c-Jun N-terminal kinase (JNK) pathway in the rats of crush injuries. Journal of Orthopaedic Surgery and Research, 2022 (PubMed: 35033142) [IF=2.6]

Application: WB    Species: Rat    Sample: lung tissue

Fig. 2 EP, FPS-ZM1, and SP600125 affect the expression of HMGB1, RAGE, and JNK in lung tissue. Relative levels of HMGB1, RAGE, and JNK were analyzed using Western blot. The HMGB1, RAGE, and p-JNK were lower in the later three pretreatment groups. Results were expressed as means ± SDs. The number of rats were 13, 12, 14, 13, and 14 in CS, CS + vehicle, CS + EP, CS + FPS-ZM1, and CS + SP600125 groups, respectively. Statistical significance: ns P ≥ 0.05, *P < 0.05 and **P < 0.01, versus CS group

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.